SCHEDULE 13D: Celadon Partners Discloses 37.6% Stake in Senti Biosciences Following Preferred Stock Conversion

Celadon Partners SPV 24 has reported a 37.6% beneficial ownership stake in Senti Biosciences, Inc. after converting Series A Preferred Stock into 9,777,000 shares of common stock.

Summary

• Celadon Partners SPV 24 and Celadon Partners, LLC (collectively, the "Reporting Persons") have filed a Schedule 13D, disclosing their beneficial ownership in Senti Biosciences, Inc.
• The Reporting Persons now beneficially own 9,777,000 shares of Senti Biosciences' Common Stock, representing 37.6% of the outstanding shares.
• This ownership resulted from the conversion of 9,777 shares of Series A Preferred Stock, which Celadon Partners SPV 24 acquired for an aggregate offering price of approximately $22.0 million.
• The Series A Preferred Stock automatically converted into Common Stock on March 10, 2025, at a conversion price of $2.25 per share, following stockholder approval on March 6, 2025.
• Celadon Partners SPV 24 also holds warrants to purchase an additional 14,665,500 shares of Common Stock at an exercise price of $2.30 per share, but these warrants are currently not exercisable due to a 9.99% beneficial ownership limitation.
• The beneficial ownership limitation can be increased to 45.00% by providing at least 61 days' prior notice to the Issuer.
• The acquisition was made for investment purposes, and the Reporting Persons may, at any time, acquire or dispose of shares, or engage in discussions with management and the board regarding potential changes to the Issuer's operations, management, or capital structure.

Sentiment

Score: 5

Explanation: This is a factual disclosure of a significant ownership change and capital infusion, not a performance report. The implications (dilution, potential control) are neutral in terms of immediate sentiment without further context on the company's financial health or strategic plans.

Positives

• Senti Biosciences received a significant capital infusion of approximately $22.0 million from Celadon Partners through the purchase of Series A Preferred Stock.
• Celadon Partners now holds a substantial 37.6% ownership stake, which could provide strategic stability and guidance to Senti Biosciences.
• A Registration Rights Agreement is in place, which will facilitate future liquidity for Celadon Partners by enabling the resale of their shares.

Negatives

• Warrants for 14,665,500 shares held by Celadon Partners are currently not exercisable due to a 9.99% beneficial ownership limitation, restricting immediate potential upside from these instruments.
• The issuance of shares upon conversion of Series A Preferred Stock and exercise of warrants occurred at prices ($2.25 and $2.30 per share, respectively) that were less than the 'minimum price' under Nasdaq Listing Rule 5635(d), and potentially constituted a 'change of control' under Nasdaq Listing Rule 5635(b), suggesting a dilutive financing event.

Risks

• Potential future dilution for existing shareholders if Celadon Partners increases its beneficial ownership limitation and exercises its warrants for an additional 14,665,500 shares.
• The beneficial ownership limitation (initially 9.99%, adjustable to 45.00%) could restrict Celadon's ability to fully exercise its warrants without prior notice, impacting their investment strategy.
• The transaction required specific stockholder approval due to the issuance of shares at less than the 'minimum price' and a potential 'change of control' under Nasdaq rules, which may indicate underlying financial challenges or a highly dilutive financing structure for Senti Biosciences.
• Future actions by Celadon Partners, including acquiring or disposing of shares, or suggesting changes to Senti Biosciences' operations, management, or capital structure, could significantly impact the company's direction and share price.

Future Outlook

Celadon Partners acquired the securities for investment purposes and may, at any time, acquire or dispose of additional shares of Common Stock or related securities. They also intend to engage in communications with Senti Biosciences' management and board of directors, potentially suggesting or taking positions on changes to the Issuer's operations, management, or capital structure to enhance shareholder value. The Issuer is obligated to file a registration statement within 120 days of December 2, 2024, to register the resale of shares held by Celadon Partners.

Industry Context

This filing indicates a significant capital infusion and a substantial change in ownership structure for Senti Biosciences, a company likely operating in the biotechnology or synthetic biology sector. Such large stakes by investment firms, especially those requiring specific stockholder approvals for Nasdaq listing rules related to 'minimum price' and 'change of control,' often occur in early-stage or financially challenged companies seeking strategic investment and capital to advance their pipeline or operations. This suggests a pivotal moment for Senti Biosciences, potentially signaling a new strategic direction or a critical financing round.

Comparison to Industry Standards

• A 37.6% beneficial ownership stake by a single investment entity like Celadon Partners is a very substantial, near-controlling interest, which is significantly higher than typical passive institutional investments in publicly traded companies. This suggests a more active, strategic role rather than a purely financial one, which is common in distressed or high-growth, early-stage biotech companies.
• The requirement for stockholder approval under Nasdaq Listing Rule 5635(d) (issuance at less than 'minimum price') and 5635(b) (potential 'change of control') indicates that the financing terms were highly dilutive or involved a significant shift in control. This is a common characteristic of financing rounds for biotech companies facing financial constraints or undergoing a major strategic pivot, where capital is critical and valuation may be secondary to securing funds, unlike more established, financially stable industry peers.

Corporate Governance

Related Party Transactions

• Mr. Donald Tang, a manager of Celadon Partners, LLC, serves as a non-employee director of Senti Biosciences, Inc. and may receive stock options or other equity-based compensation from the Issuer.

Stakeholder Impact

• Shareholders: Experience significant dilution from the conversion of Series A Preferred Stock and face potential future dilution if warrants are exercised. The entry of a large new shareholder (Celadon Partners) with a 37.6% stake could significantly influence future strategic direction and corporate governance.
• Company (Senti Biosciences): Benefited from a capital infusion of approximately $22.0 million, which can be used for operations and strategic initiatives.

Next Steps

• Celadon Partners may acquire or dispose of additional shares of Common Stock or securities convertible, exchangeable, or exercisable into Common Stock.
• Celadon Partners may provide 61 days' prior notice to Senti Biosciences to increase its beneficial ownership limitation up to 45.00%, which would enable the exercise of its warrants.
• Senti Biosciences is obligated to file a registration statement under the Securities Act of 1933 within 120 days after December 2, 2024, to register the resale of shares beneficially owned by the holders, including Celadon Partners.
• Celadon Partners may engage in communications with other shareholders, officers, and board members of Senti Biosciences regarding the Issuer's operations, management, or capital structure.
• Celadon Partners may suggest or take a position with respect to potential changes in the operations, management, or capital structure of Senti Biosciences to enhance shareholder value.

Key Dates

Keywords

Senti Biosciences, Celadon Partners, Schedule 13D, Beneficial Ownership, Common Stock, Series A Preferred Stock, Warrants, SEC Filing, Investment, Corporate Governance, Nasdaq Listing Rules, Capital Raise, Dilution